Skip to main content

EUROpean consortium for antiCALINs as next generation high-affinity protein therapeutics

Obiettivo

The consortium aims to develop and produce an Anticalin, a member of a novel high-affinity scaffold derived from the lipocalin protein family. The Anticalin is specific for hepcidin which is a central regulator of iron homeostasis, and will be used to antagonize hepcidin for the treatment of “anemia of chronic disease” (ACD). Anticalins are genetically modified lipocalins that can target almost any desired molecule. Unlike Immunoglobulins, they can be produced at low cost in microbial expression systems, are expected to be non immunogenic and offer therapeutic advantages where antibody effector functions are not desired. ACD, the most frequent anemia in hospitalized patients, develops in subjects suffering from infections, inflammatory and auto-immune disease, cancer and chronic kidney disease. It is often successfully treated by administering Erythropoiesis-Stimulating Agents. However, a significant number of patients are hypo- or non-responsive to ESA. Anti-hepcidin therapies, alone or together with ESAs, may improve anemia and the patients’ erythropoietic response and enable the use of no or even much lower ESA doses, avoiding the potential detrimental effects of high doses of ESA. The Consortium has already generated proof-of-concept data in an animal model with early candidates. The project aims at identifying, validating, and developing a specific, high affinity drug candidate based on the lipocalin scaffold as promising alternatives to immunoglobulins and a therapeutic approach based on the neutralization of hepcidin. Animal models will be developed and utilized to characterize pharmacokinetic and pharmacodynamic relationships, optimize dosing, to determine safety, biomarker responses and potential synergy with ESA’s. Furthermore, production processes will be optimized leading to a scalable GMP process which provides material for preclinical and clinical studies to establish the safety, tolerability, and PK/PD of an Anticalin hepcidin blocker (Phase Ia/b).

Invito a presentare proposte

FP7-HEALTH-2011-two-stage
Vedi altri progetti per questo bando

Meccanismo di finanziamento

CP-FP - Small or medium-scale focused research project

Coordinatore

PIERIS PHARMACEUTICALS GMBH
Indirizzo
Lise-meitner-straße 30
85354 Freising
Germania
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contributo UE
€ 2 164 000
Contatto amministrativo
Rita Fischer (Mrs.)

Partecipanti (10)

TECHNISCHE UNIVERSITAET MUENCHEN
Germania
Contributo UE
€ 261 600
Indirizzo
Arcisstrasse 21
80333 Muenchen
Tipo di attività
Higher or Secondary Education Establishments
Contatto amministrativo
Ulrike Ronchetti (Ms.)
MEDIZINISCHE UNIVERSITAT INNSBRUCK
Austria
Contributo UE
€ 416 200
Indirizzo
Christoph Probst Platz 1
6020 Innsbruck
Tipo di attività
Higher or Secondary Education Establishments
Contatto amministrativo
Guenter Weiss (Prof.)
STICHTING KATHOLIEKE UNIVERSITEIT
Paesi Bassi
Contributo UE
€ 494 340
Indirizzo
Houtlaan 4
6525 XZ Nijmegen
Tipo di attività
Higher or Secondary Education Establishments
Contatto amministrativo
Maarten Van Langen (Mr.)
COVANCE LABORATORIES LTD
United Kingdom
Contributo UE
€ 456 800
Indirizzo
Otley Road
HG3 IPY Harrogate
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contatto amministrativo
Carol Noble (Ms.)
ANTITOPE LIMITED
United Kingdom
Contributo UE
€ 263 040
Indirizzo
Babraham Research Campus
CB22 3AT Cambridge
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contatto amministrativo
Frank Carr (Dr.)
FUJIFILM DIOSYNTH BIOTECHNOLOGIES UK LIMITED
United Kingdom
Contributo UE
€ 1 109 963,50
Indirizzo
Belasis Avenue
TS23 1LH Billingham
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contatto amministrativo
Lyons Mike (Mr.)
CORIOLIS PHARMASERVICE GMBH

Partecipazione conclusa

Germania
Contributo UE
€ 92 734,16
Indirizzo
Am Klopferspitz 19
82152 Martinsried
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contatto amministrativo
Thomas Wiggenhorn
FGK CLINICAL RESEARCH GMBH
Germania
Contributo UE
€ 271 200
Indirizzo
Heimeranstrasse 35
80339 Munchen
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contatto amministrativo
Ina Ott (Mrs.)
CONSULTECH TECHNOLOGIEBERATUNG GMBH
Germania
Contributo UE
€ 309 800
Indirizzo
Morgensternstrasse 24
12207 Berlin
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contatto amministrativo
Daniel Schubart (Dr.)
CORIOLIS PHARMA RESEARCH GMBH*
Germania
Contributo UE
€ 156 625,84
Indirizzo
Am Klopferspitz 19
82152 Martinsried
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contatto amministrativo
Thomas Wiggenhorn